

Title:

High heritability of ascending aortic diameter and multi-ethnic prediction of thoracic aortic disease.

Authors:

Catherine Tcheandjieu^{1,2,3}, Ke Xiao^{1,\$}, Helio Tejada¹, Julie A. Lynch^{4,5}, Sanni Ruotsalainen⁶, Tiffany Bellomo^{7,8,9}, Madhuri Palnati¹⁰, Renae Judy^{7,8}, Derek Klarin^{11,12}, Rachel Kember^{7,8,9}, Shefali Verma¹³, Regeneron Genetics Center¹⁴, VA Million Veterans Program, FinnGen Project, Aarno Palotie⁶, Mark Daly⁶, Marylyn Ritchie¹³, Daniel J. Rader^{8,13}, Manuel A. Rivas¹⁵, Themistocles Assimes^{2,3}, Philip Tsao^{2,3}, Scott Damrauer^{7,9}, James R. Priest^{1,16}

Affiliations:

1. Department of Pediatrics – Division of Pediatric Cardiology, Stanford University School of Medicine, Stanford, CA
2. Department of Medicine-- Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA
3. VA Palo Alto Health Care System, Palo Alto, CA
4. Veterans Affairs Informatics and Computing Infrastructure, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT
5. University of Massachusetts College of Nursing & Health Sciences, Boston, MA, USA (JL)
6. Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland (SR)
7. Corporal Michael Crescenz VA Medical Center, Philadelphia, PA
8. Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
9. Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
10. Center for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, USA
11. VA Boston Healthcare System, Boston, MA
12. Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA,
13. Department of Genetics, University of Pennsylvania, Philadelphia, PA, USA
14. Regeneron Genetics Center, Regeneron Pharmaceuticals Inc., Tarrytown, NY
15. Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA,
16. Chan-Zuckerberg Biohub, San Francisco, CA

\$ Current affiliation: College of Information & Computer Science, University of Massachusetts, Amherst, MA

Corresponding Author:

James R. Priest MD
Assistant Professor, Pediatric Cardiology
Stanford University School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Tel: (510) 213-2043
Fax: (650) 498-7452
email: jpriest@stanford.edu

ABSTRACT

Enlargement of the aorta is an important risk factor for aortic aneurysm and dissection, a leading cause of morbidity in the developed world. While Mendelian genetics account for a portion of thoracic aortic disease, the contribution of common variation is not known. Using standard techniques in computer vision, we performed automated extraction of Ascending Aortic Diameter (AsAoD) from cardiac MRI of 36,021 individuals from the UK Biobank. A multi-ethnic genome wide association study and trans-ethnic meta-analysis identified 99 lead variants across 71 loci including genes related to cardiovascular development (*HAND2*, *TBX20*) and Mendelian forms of thoracic aortic disease (*ELN*, *FBN1*). A polygenic risk score predicted prevalent risk of thoracic aortic aneurysm within the UK Biobank (OR 1.50 per standard deviation (SD) polygenic risk score (PRS), $p=6.30 \times 10^{-03}$) which was validated across three additional biobanks including FinnGen, the Penn Medicine Biobank, and the Million Veterans Program (MVP) in individuals of European descent (OR 1.37 [1.31 - 1.43] per SD PRS), individuals of Hispanic descent (OR 1.40 [1.16 - 1.69] per SD PRS, $p=5.6 \times 10^{-04}$), and individuals of African American descent (OR 1.08 [1.00 - 1.18] per SD PRS, $p=0.05$). Within individuals of European descent who carried a diagnosis of thoracic aneurysm, the PRS was specifically predictive of the need for surgical intervention (OR 1.57 [1.15 - 2.15] per SD PRS, $p=4.45 \times 10^{-03}$). Using Mendelian Randomization our data highlight the primary causal role of blood pressure in reducing dilation of the thoracic aorta. Overall our findings link normal anatomic variation to extremes observed in Mendelian syndromes and provide a roadmap for the use of genetic determinants of human anatomy in both understanding cardiovascular development while simultaneously improving prediction and prevention of human disease.

INTRODUCTION

The thoracic aorta originates from multiple developmental anlage to become the largest vascular structure in the human body which receives and distributes oxygenated blood pumped by the left ventricle¹. Body surface area is a primary determinant of thoracic aortic size, which increases in diameter with the physiological demands that accompany normal growth throughout childhood and into adult life². Extremes in thoracic aortic diameter can manifest in clinically significant disease ranging from thoracic aortic dilation or aneurysm which may be asymptomatic until the occurrence of rupture or dissection³⁻⁵.

Common genetic variation has been associated with echocardiographic measurement of aortic root diameter within European populations⁶. Heritable differences in the size of the aortic root are present within family members of individuals with congenital malformations of the aorta⁷, and clinical genetic testing for known mendelian forms of aortopathy are an integral part of multidisciplinary care for thoracic aortic disease⁸. However, for up to 75% of individuals affected with thoracic aortic disease, pathogenic mendelian variation is not found on clinical genetic testing and risk factors such smoking and hypertension are often insufficient to explain incident pathology⁹ which suggests that a substantial portion of risk for thoracic aortic disease has yet to be described.

Here we report a genome wide association study of ascending aorta diameter (AsAoD) – extracted using machine learning – from a population-based study of 36,021 cardiac MRI prospectively obtained by the UK Biobank organization. We report 71 new genomic risk loci associated with ascending aorta diameter which explain a large proportion of the total heritability in observed variation in the AsAoD and showed that the polygenic risk score of the AsAoD is predictive for the risk of thoracic aortic aneurysm across multiple populations.

RESULTS

Ascending Aorta Diameter (AsAoD) measurement

The AsAoD was derived from a transverse MRI image of the thorax (figure 1a) using a simple segmentation-based approach (see methods section) in 36,021 UK Biobank participants.

Overall, in concordance with existing normal data of aortic size, the mean of the AsAoD was 30.6 mm (sd=3.9) in females and 33.3 mm (sd=4.2) in males (figure 1b-1c).




Figure 1: (a) Transverse plane image of the thorax from cardiac MRI, label in yellow is ascending aorta diameter (aa). (b) Violin plots ascending aorta diameter area in female (red) and in male (blue) (table S1). (c) Scatter plot of ascending aortic diameter by body surface area in female (red) and in male (blue). As expected from the general population^{10,11}, females had on average a smaller aorta area than males. (d) distribution of AsAoD by genetic ancestry (e)

Manhattan plots of AsAoD ethnic-specific GWAS and the trans-ethnic meta-analysis. The dashed line represents a standard threshold of significance (5×10^{-08})

Ancestry-specific and trans-ethnic meta-analysis of AsAoD

We first performed a genome wide association study (GWAS) of AsAoD adjusted for body surface area in unrelated white European ($n = 32,215$) in the UK Biobank observing a striking set of 163 independent variants across 42 genomic loci (figure 1e, figure S1, table S2). Using GREML-LDMS within the Europeans, we estimated a high-level of heritability at 0.398 ($se=0.072$) derived from individual level imputed and genotyped variants with a contribution of variants spread across all range of allele frequencies and a strong contribution of common variants ($MAF > 0.1$) in the heritability estimate (figure S1). Therefore, we elected to perform a GWAS of AsAoD in the African and Afro-Caribbean ($n = 262$), East Asian ($n = 133$) and South Asian participants ($n = 441$) with MRI data in the UK biobank followed by a transethnic meta-analysis of all individuals (figure S2).

We identified a total of 71 genomic risk (table 1) loci associated with AsAoD among which 45 signals were consistent across all ethnic groups ($p_{het} > 1e-03$), three of these loci reach genome wide significance in the trans-ethnic meta-analysis, 37 loci were significant in the European GWAS; and six loci with African specific lead variants had candidate variants in or near the locus in another ancestry group (table 1, figure S2, table S2). Five genomic risk loci were present only in Europeans while 18 loci were African/Afro-Caribbean specific risk loci among which 3 loci (5q35 (*CAMK2A*), 18q11 (*NAPG*), and 21q22 (*COL18A1*)) were suggestive in Europeans with consistent directionality across all ethnic strata but with significant heterogeneity in the transethnic meta-analysis (figure S3, table S2). Two loci were significant in South Asians with the direction of effect consistent with other ethnic strata but displaying high heterogeneity in the trans-ethnic meta-analysis.

The strongest signal was found in the locus 7q11.2 near Elastin (*ELN*), a gene responsible for elastin production, a key component of elastic fiber structure of vascular tissue including the aorta. The second strongest independent signal was observed in the locus 5p23 near *PCSK1* a proprotein Convertase Subtilisin/Kexin Type 1. Within the African/Afro-Caribbean strata the two strongest signals were found in the locus 4q32 (*AGAP1*) and 4q35 (*ANKRD37*) overlapping the 4q deletion syndrome region which includes a key transcription factor in cardiac development *HAND2*¹²⁻¹⁴. Interestingly, we observed a separate distinct GWAS signal in Europeans at the 4q32 locus (table 1, figure S3) with effect sizes consistent across all ancestries (table S3).

1 Table 1: Lead variants in each genomic loci for ancestry specific and the trans-ethnic meta-
 2 analysis of AsAoD.

nLocus	rsid	chr	pos	annot	genes	nLead SNPs	A1	EAF	BETA	P	Annotation
1	rs191029806	1	5098276	intergenic	AJAP1-RP11-542C10.1	1	T	1.24E-02	2.24	1.56E-09	AFR specific
2	rs59882254	1	185694984	intergenic	GS1-204112.4-HMCN1	1	A	0.26	0.05	1.62E-09	GWAS in EUR and phet <0.05 in TEM
3	rs2745939	1	208142081	intergenic	CD34-PLXNA2	1	A	0.64	-0.04	1.29E-08	GWAS in EUR and phet <0.05 in TEM
4	rs76761944	2	12813757	intergenic	AC096559.2-RP11-3330.1	1	A	0.03	0.98	7.41E-09	GWAS hit from TEM
5	rs35786425	2	19720133	intergenic	AC010096.2-AC019055.1	2	G	0.32	0.07	5.72E-20	GWAS in EUR and phet <0.05 in TEM
6	rs142695462	2	150669907	ncRNA_intronic	AC007364.1-AC144449.1	1	A	1.49E-02	2.09	3.04E-08	AFR specific
7	rs139996344	2	164642984	ncRNA_intronic	AC092684.1	1	A	0.02	1.45	4.82E-09	AFR specific
8	rs151286392	2	236324241	intergenic	AC092576.1-AGAP1	1	T	0.02	1.82	2.78E-08	AFR specific
9	rs73028182	3	14863636	intronic	FGD5	1	A	0.87	0.06	6.32E-09	GWAS in EUR and phet <0.05 in TEM
10	rs111821658	3	4170466	intronic	ULK4	3	C	0.88	-0.08	4.26E-12	GWAS in EUR and phet <0.05 in TEM
11	rs2686630	3	58091861	intronic	FLNB	1	C	0.36	-0.05	4.62E-11	GWAS in EUR and phet <0.05 in TEM
13	rs79692190	3	74222764	intergenic	Y_RNA-CNTN3	T	1.31E-02	1.47	3.36E-08	GWAS in SAS (het >1e-06 in the TEM)**	
51	rs75646195	14	47247998	intergenic	MDGA2	A	1.19E-02	1.29	2.62E-08	GWAS in SAS (het >1e-06 in the TEM)**	
14	rs55914222	3	128202943	intronic	GATA2	1	C	0.03	-0.16	2.13E-13	GWAS in EUR and phet <0.05 in TEM
15	rs698083	3	186997742	intronic	MASP1	1	T	0.17	0.06	4.17E-10	GWAS in EUR and phet <0.05 in TEM
16	rs11100902	4	146795226	intronic	ZNF827	1	A	0.48	-0.04	3.86E-08	GWAS in EUR and phet <0.05 in TEM
17*	rs190553581	4	167191041	intergenic	AC092576.1-AGAP1	1	A	0.99	-1.74	4.59E-10	GWAS in AFR with candidate variants in other ethnic
18*	rs67846163	4	174656889	intergenic	RANP6-RP11-161D15.2	1	A	0.77	-0.06	7.59E-13	GWAS in EUR and phet <0.05 in TEM
19*	rs527856231	4	186319294	intronic	ANKRD37	3	T	1.35E-02	1.77	1.55E-09	GWAS in AFR with candidate variants in other ethnic
20	rs17309061	5	44249820	intergenic	RNU6-381P-FGF10	1	A	0.84	0.06	3.19E-08	GWAS hit from TEM
21	rs149783640	5	81774446	intergenic	CTD-2015A6.1	1	T	0.79	0.06	3.03E-11	GWAS in EUR and phet <0.05 in TEM
22	rs4077816	5	95582494	ncRNA_intronic	CTD-2337A12.1	10	A	0.63	0.09	1.49E-33	GWAS in EUR and phet <0.05 in TEM
23	rs337086	5	122555501	intergenic	PRDM6-CTD-2347117.1	4	A	0.33	0.05	5.15E-12	GWAS in EUR and phet <0.05 in TEM
24	rs145765024	5	149615389	intronic	CAMK2A	1	A	0.02	1.80	3.81E-09	GWAS in AFR with candidate variants in other ethnic
25	rs1630736	6	12295987	intronic	EDN1	2	T	0.46	0.05	7.16E-13	GWAS in EUR and phet <0.05 in TEM
26	rs147796331	6	21519596	intergenic	P1-135L22.1-RP11-204E9.	1	T	0.99	-1.97	6.53E-09	GWAS in AFR with candidate variants in other ethnic
27	rs545416745	6	45706564	intergenic	RUNX2-CLIC5	1	C	1.00	-1.36	4.82E-08	EUR specific
28	rs143647487	6	124348835	intronic	NKAIN2	1	T	9.00E-04	0.79	1.12E-09	EUR specific
29	rs1570350	6	1436592386	intronic	AIG1	1	A	0.56	-0.04	4.68E-09	GWAS in EUR and phet <0.05 in TEM
30	rs2429416	7	35276634	intronic	TBX20	2	T	0.64	0.05	1.17E-09	GWAS in EUR and phet <0.05 in TEM
31	rs6460067	7	73426721	intergenic	RP11-731K22.1-ELN	4	A	0.46	0.11	4.77E-53	GWAS in EUR and phet <0.05 in TEM
32	rs2463481	7	85037374	intergenic	AC073958.2-LINC00972	1	A	0.61	-0.07	5.22E-21	GWAS in EUR and phet <0.05 in TEM
33	rs9721183	8	75781818	intergenic	P11-758M4.4-RP11-3N13.1	1	T	0.37	-0.05	3.64E-09	GWAS in EUR and phet <0.05 in TEM
34	rs149133670	8	108295235	intronic	ANGPT1	1	G	0.77	-0.05	1.92E-08	GWAS in EUR and phet <0.05 in TEM
35	rs147554310	8	112373835	intergenic	P11-946L20.4-RP11-1101KE	1	A	0.98	-1.51	2.92E-08	AFR specific
36	rs18669472	8	120701930	intergenic	ENPP2-RN7SKP153	2	T	2.70E-03	-0.59	1.30E-14	EUR specific
37	rs1238647271	8	122634926	intronic	HAS2	2	CA	0.67	0.05	9.92E-12	GWAS in EUR and phet <0.05 in TEM
38	rs2891781	8	124608162	intergenic	RN7SKP155-CTD-2552K11.1	1	T	0.37	0.05	5.04E-13	GWAS in EUR and phet <0.05 in TEM
39	rs145779592	9	6101949	intergenic	P11-21817.2-RP11-575C20.	1	T	1.25E-02	1.63	2.24E-08	GWAS in AFR with candidate variants in other ethnic
40	rs565464483	9	129806559	intronic	RALGPS1	1	C	3.00E-04	1.31	8.08E-09	EUR specific
41	rs35751397	10	64914016	UTR3	NRBF2	1	T	0.53	0.04	2.91E-09	GWAS in EUR and phet <0.05 in TEM
42	rs12771055	10	96116420	intronic	NOC3L	1	A	0.84	0.06	4.48E-10	GWAS in EUR and phet <0.05 in TEM
43	rs144109572	10	119213909	ncRNA_intronic	CTA-109P11.4	1	A	1.47E-02	1.71	4.21E-08	AFR specific
12	rs11927332	3	70606921	intergenic	RP11-231113.2-COX6CP6	1	A	0.16	0.63	1.26E-08	GWAS in AFR (het >1e-06 in the TEM)**
45	rs113882855	11	69832430	ncRNA_intronic	RP11-626H12.1	2	A	0.08	0.09	2.99E-11	GWAS in EUR and phet <0.05 in TEM
46	rs142058488	12	3966299	intronic	PARP11	1	C	0.03	1.36	1.98E-08	AFR specific
47	rs11046213	12	22008367	ncRNA_intronic	RP11-729I10.2	1	T	0.41	-0.05	3.86E-11	GWAS in EUR and phet <0.05 in TEM
48	rs17661264	12	62804079	intronic	USP15	1	T	0.89	-0.07	4.01E-09	GWAS in EUR and phet <0.05 in TEM
49	rs9510086	13	22862440	intergenic	MTND3P1-FTH1P7	2	C	0.22	-0.09	1.49E-27	GWAS in EUR and phet <0.05 in TEM
50	rs142613969	13	67797027	intronic	PCDH9	1	A	1.22E-02	2.03	3.63E-08	AFR specific
44	rs531076248	10	127940352	intronic	ADAM12	1	T	1.38E-02	1.84	2.52E-08	GWAS in AFR (het >1e-06 in the TEM)**
52	rs114910738	14	73414561	intronic	DCAF4	1	T	0.02	1.58	1.31E-08	AFR specific
53	rs11848552	14	94460685	intergenic	ASB2-LINC00521	2	A	0.40	-0.05	2.85E-10	GWAS in EUR and phet <0.05 in TEM
54	rs595244	15	48840835	intronic	FBN1	1	T	0.09	0.07	2.87E-08	GWAS in EUR and phet <0.05 in TEM
55	rs1441358	15	71612514	intronic	THSD4	1	T	0.66	0.05	5.84E-10	GWAS in EUR and phet <0.05 in TEM
56	rs7168391	15	79055163	intronic	ADAMTS7	1	T	0.43	0.04	4.50E-08	GWAS hit from TEM
57	rs74029577	15	89581233	ncRNA_exonic	RP11-326A19.2	1	A	1.22E-02	1.72	3.64E-08	AFR specific
58	rs73468486	15	96104247	intergenic	LINC00924-RNU2-3P	1	A	0.98	-1.33	3.76E-08	AFR specific
59	rs62053262	16	69969299	intronic	WWP2	1	C	0.95	0.16	2.18E-23	GWAS in EUR and phet <0.05 in TEM
60	rs16965180	16	88989862	intronic	CBFA2T3	1	A	0.65	0.05	2.96E-12	GWAS in EUR and phet <0.05 in TEM
61	rs2224770	17	2205923	intronic	SMG6	3	T	0.38	0.06	2.73E-15	GWAS in EUR and phet <0.05 in TEM
62	rs7221449	17	12191884	intergenic	RP11-471L13.2-LINC00670	1	T	0.44	-0.05	1.69E-13	GWAS in EUR and phet <0.05 in TEM
63	rs148898750	17	65025944	intronic	CACNG4	1	T	1.21E-02	2.30	4.26E-10	AFR specific
64	rs149302052	18	1578012	ncRNA_intronic	RP11-476K15.1	1	C	3.00E-04	1.24	7.56E-08	EUR specific
65	rs534590349	18	10629880	ncRNA_intronic	RP11-856M7.6	1	A	1.46E-02	1.98	4.63E-09	GWAS in AFR (het >1e-06 in the TEM)**
66	rs75268348	18	75290173	intergenic	P11-176N18.2-RP11-63N3.	1	A	1.32E-02	1.89	4.24E-08	GWAS in AFR (het >1e-06 in the TEM)**
67	rs113785523	20	6289974	intergenic	AL109618.1-CASC20	1	T	0.98	-1.61	5.01E-09	GWAS in AFR with candidate variants in other ethnic
68	rs141953403	20	15543319	intronic	MACROD2	1	A	0.03	1.28	2.61E-08	AFR specific
69	rs4819101	21	46835361	intronic	COL18A1	1	G	0.67	-0.46	6.95E-09	GWAS in AFR (het >1e-06 in the TEM)**
70**	rs59549616	22	40547556	intronic	TNR06B	2	A	0.45	0.04	2.15E-09	GWAS in EUR and phet <0.05 in TEM
71	rs8137282	22	42211789	intronic	CCDC134	1	C	0.97	0.11	4.41E-08	GWAS in EUR and phet <0.05 in TEM

* highlighted are the genomic loci overlapping the cardiovascular critical region 4q32-34
 **Genomic locus that did not reach did not reach GWAS in the trans-ethnic meta-analysis

3
 4
 5 Variant function prediction and chromatin interaction

6 To identify variants which alter gene expression or protein function we annotated variants with
7 $p < 1 \times 10^{-05}$ using Haploreg¹⁵. Overall, we identified 16 non-synonymous variants located in
8 several genes including *ELN*, *ULK4*, and *SMG6*; six variants in promoter regions of *MASP1*,
9 *TBX20*, *CDKN1A*, and *HAS-AS1*. Several other variants were located in transcription factors
10 binding sites (TFBs) or in region with high chromatin interaction targeting promoter or enhancer
11 of several genes (table S4).

12

13 To further investigate the relationship between genes inside or outside the genomic risk loci, in
14 each independent signal we mapped genes whose promoter or enhancer overlapped with
15 independent variants displaying significant eQTL or chromatin interactions using FUMA^{16,17}.
16 Chromatin interaction and eQTLs were observed for multiple loci (figure S4). For instance,
17 strong chromatin interactions were observed between enhancer and promoter of *PCSK1*, *ELL2*,
18 *ERAP1*, *ERAP2*, *RHOBTB3* and *GLRX* in the genomic risk locus 5p23. Similarly, chromatin
19 interaction was observed between *ELN* in the locus 7q11 and enhancers or promoters of
20 several genes including *TBL2*, *LIMK2*, *CLIP2*. Additionally, variants in *ELN*, *LAT2* and
21 *GTF2IRD1* display significant eQTLs in multiple tissues including aorta (figure S4).


22

23 **Genes enrichment and transcriptome-wide association analysis**

24 We used MAGMA to leverage our summary statistics to examine gene-level associations,
25 testing 19,288 annotated genes tagged by variants from our GWAS summary. After multiple
26 testing correction, we identified 267 genes significantly associated with AsAoD (table S5)
27 including genes well described in mendelian diseases affecting the aorta *ELN*, *JAG1*, *EDN1*,
28 *LOX*, and *FBN1*. We further evaluated the association of imputed tissue-specific gene
29 expression levels with AsAoD risk across multiple tissues and cells using S-PrediXcan. We then
30 used COLOC to formally assess the posterior probability of true colocalization events between
31 gene expression and AsAoD. Predicted levels of fibroblasts growth factor 9 (*FGF9*) which has

32 been shown to play an important role in aorta development, and *PRDM6* levels both associated
33 with AsAoD (figure 2a). We identified 35 gene-tissue pairs (table S7), among which 18 genes
34 colocalize to the expression in the aorta and the strongest were *PRDM6*, *HMCN1*, and *HAND2*
35 which also displayed expression in coronary arteries, atrial appendage, and left ventricle (figure
36 2b). Finally, we performed a tissue enrichment association test using MAGMA (implemented in
37 the FUMA (<https://fuma.ctglab.nl/>)) to identify the set of tissue with significant eQTL enrichment
38 with AsAoD using our GWAS summary statistics and 58 tissues available in Gtex V8. We found
39 significant tissue enrichment for tibial arteries, aorta, coronary arteries, endocervix, colon
40 sigmoid, and ovary which all reflect a predominance of smooth muscle cells in these tissues.

41



42
 43 Figure 2: Enrichment of gene-tissue expression pairs within the GWAS of AsAoD (top). The
 44 outlines indicate gene sets significantly expressed in aorta and smooth muscle related tissues.
 45 (bottom) A subset of gene-tissue pairs significantly enriched in the transcriptome-wide
 46 association analysis (S-PrediXcan) and colocalizing in selected tissues of relevance.

47

48 Assessment of pleiotropy

49 To evaluate the pleiotropic effect of AsAoD risk loci, we extracted all previously reported
 50 associations with AsAoD or in high LD with a variant significantly associated with AsAoD from

51 the GWAS catalog. Variants at 31 genomic risk loci were previously associated with multiple
52 phenotypes including aortic root size measured by echocardiography, carotid intima media
53 thickness, abdominal aortic aneurysm, blood pressure (diastolic BP, systolic BP and pulse
54 pressure), coronary artery disease, and a number of blood count measurement and blood
55 biomarkers (figure S5, table S6). We further investigated which of the phenotypes have a high
56 enrichment of GWAS signal in the AsAoD GWAS by comparing the proportion of overlapping
57 genes between the AsAoD and traits reported in the GWAS catalog. We observe a high
58 enrichment of genes previously associated with diastolic blood pressure, pulse pressure, and
59 aortic root size (figure S5), suggesting a high genetic correlation between these traits and
60 AsAoD.

61

62 **Genetic correlation**

63 We estimated the genetic correlation between AsAoD GWAS and known clinical risk factors
64 associated with aortic aneurysm such as blood pressure and lipid biomarkers using currently
65 publicly available GWAS summary statistic as well as 238 previously reported traits available on
66 LD Hub v1.9.3 (<http://ldsc.broadinstitute.org>) (figure S6, table S6). We found a significant
67 genetic correlation between blood pressure and AsAoD ($rg=0.31$, $p.fdr=7.3 \times 10^{-19}$ for diastolic
68 blood pressure; $rg=0.13$, $p.fdr=45.3 \times 10^{-03}$ for systolic blood pressure) while no significant
69 genetic correlation was observed for lipid biomarkers. Moreover, among others traits analyzed,
70 we found a significantly high genetic correlation with anthropometric traits including birth weight
71 ($rg=0.27$, $p.fdr=6 \times 10^{-11}$), height ($rg=0.21$, $p.fdr=4 \times 10^{-05}$), body mass index ($rg=0.18$, $p.fdr=1 \times 10^{-03}$);
72 inversely, we found a significant negative correlation between Autism spectrum disorder and
73 AsAoD ($rg=-0.27$, $p.fdr=0.01$).

74


75 **Polygenic risk score association with Aortic disease**

76

77 To evaluate whether the enlargement of the aorta can predict the risk of aortic aneurysm, we
78 developed a polygenic risk score (PRS) of AsAoD using the summary statistics of a GWAS
79 performed in a training set of 20,642 unrelated white European using a standard pruning and
80 thresholding method. The PRS was then validated in a separate set of 12,311 UK Biobank
81 participants with cardiac MRI who did not contribute to the original variant effect estimate for the
82 PRS. The association with AsAoD was performed using linear regression adjusting for body
83 surface area (BSA), sex and the top 10 genetic principal components. Sensitivity analyses were
84 performed by stratifying by sex. The PRS with the best predictive performance included 92,299
85 variants with $R^2 < 0.8$ and $p < 0.01$. Within the validation set a 1 standard deviation (SD) increase
86 in the PRS corresponded to 0.64 mm increase in ascending aortic diameter ($\beta = 0.64$ (per SD),
87 $p = 2.5 \times 10^{-73}$) (figure S7). As expected, the effect estimate was larger in males ($\beta = 0.69$,
88 $p = 2.5 \times 10^{-38}$) than in females ($\beta = 0.59$, $p = 2.3 \times 10^{-37}$) (figure S4).

89 We examined the association between the PRS of AsAoD and aortic aneurysm in an
90 independent subset of the UK Biobank participants without cardiac MRI measurement at the
91 time of the analysis ($n = 314,560$). Increased PRS for AsAoD was associated with both increased
92 risk of thoracic aortic aneurysm (OR=1.50; $p = 6.3 \times 10^{-03}$, figure 3a) and increased risk of surgical
93 intervention (OR= 1.44, $p = 1.4 \times 10^{-03}$; figure S7). In a survival analysis, 1 SD increase in the PRS
94 was predictive of 1.42 fold increased risk of thoracic aneurysm (HR=1.42, $p = 0.01$) in the UK
95 biobank (figure 3b). The association with thoracic aortic aneurysm was also replicated in
96 Europeans from the FinGenn biobank, the Million Veterans Project (MVP) and the Penn
97 Medicine Biobank (figure 3a) as well as Hispanic Americans from the MVP, and African
98 Americans from the MVP and Penn Biobanks (figure 3a). The association with PRS AsAoD was
99 even stronger amongst patients who underwent a repair of ascending aortic aneurysm
100 (OR=1.52, $p = 9 \times 10^{-03}$; figure S8). Similarly, in the MVP, we observed an OR of 1.57 ($p = 4.5 \times 10^{-03}$)
101 among patients of European ancestry, who underwent a thoracic repair after a diagnosis of
102 thoracic aortic aneurysm (figure S8). This finding suggests that, the PRS for larger aortic

103 diameter yields predictive power for thoracic aneurysm that requires eventual surgical
 104 intervention.
 105



106 OR Thoracic Aortic Aneurysm for 1 SD increase of PRS(AsAoD) in the UK biobank, the Million Veteran Program, FINGENN and Penn biobank

Competing risks model (thoracic aneurysm vs. death) adjusted for sex, age at recruitment, smoking, SBP, DBP in the UK biobank

107
 108 Figure 3: (a) Association between PRS of AsAoD and risk of thoracic Aortic aneurysm and/or
 109 thoracic aortic aneurysmal repair across four population-scale biobanks. (b) A competing-risks
 110 survival model over a median follow-up time of 29 years for incident thoracic aortic aneurysm
 111 (diagnosis or repair) adjusted for smoking, prevalent hypertension, and sex. UKB participants
 112 were divided into three tranches based on PRS for display (c) A PheWAS of the PRS of AsAoD
 113 and all UKB phenotypes.

114


115 We performed a phenome-wide association study (PheWAS) between the PRS of AsAoD on all
116 the UK Biobank phenotypes/traits available in the global biobank engine¹⁸ and ICD-10 derived
117 phecodes (tables S8 & S9). Overall, increase in physical measurement such as height, weight,
118 body fat percent, and diastolic blood pressure were significantly associated with 1 SD increase
119 in the PRS while lipid biomarkers (low density lipoprotein (LDL), total cholesterol (TC),
120 triglycerides (TG) and Apolipoprotein B) were inversely associated with an increase in the PRS
121 (figure 3). Additionally, an increase in the PRS was associated with an increased risk of
122 hypertension, increase in erythrocyte and platelet counts, and an increase in serum bilirubin
123 levels (figure 3).

124

125 **Mendelian randomization**

126

127 Finally, we investigated the causal relationship between clinical risk factors for ascending aortic
128 dilatation using mendelian randomization (MR) with systematic assessment of heterogeneity
129 and horizontal pleiotropy using MR-presso (tables S10-13, figure S9). Using the inverse-
130 variance weighted method we observed that a genetic 10 mmHg increase in diastolic and
131 systolic blood pressure was causal for a one mm increase in the diameter of the ascending
132 aorta ($\beta=0.01$ ($p=4.4 \times 10^{-06}$), and $\beta=0.02$ ($p=1.6 \times 10^{-03}$) for both systolic blood pressure (SBP)
133 and diastolic blood pressure (DBP) respectively (figure 4) without showing evidence of
134 heterogeneity or horizontal pleiotropy (table S11). No causal relationship was observed for
135 pulse pressure, LDL, high density lipoprotein (HDL), TC, TG, or lipoprotein(a).



136

137 Figure 4: Forest plot depicting causal effect estimates from mendelian randomization analysis
 138 testing the association of traditional clinical risk factors with AsAoD. Effect estimates are
 139 derived from Inverse Variants Weighted (IVW) analyses and expressed in SD change in AsAoD
 140 per SD change in exposure.

141

142 DISCUSSION

143 In this study, we used a computationally extracted vascular phenotype derived from automated
 144 segmentation of prospectively obtained cardiac MRI images from 36,095 UK Biobank
 145 participants to characterize the genetic architecture of the diameter of the ascending aorta. The
 146 automated measurements of AsAoD in our study population was similar to expected
 147 distributions derived from studies of the general population^{10,11}. Moreover, our automated
 148 measurements scaled anthropometrically as the observed AsAoD was on average higher in
 149 males than females and strongly correlated with body surface area^{19,20}.

150

151 We identify 99 lead variants across 71 loci genomic loci with across ancestries associated with
 152 variation in the ascending aorta diameter among which the strongest signal was found at 7p11.2
 153 near Elastin (*ELN*). *ELN* encodes a structural protein that is a major component of the aortic

154 wall^{21,22} and contributes to the elastic properties of many tissues including skin and lung. Loss of
155 heterozygosity in *ELN* is associated with Williams syndrome characterized by supraventricular
156 aortic stenosis (SVAS) resulting from a loss of elastin formation in the intracellular matrix and
157 consequent weakening of connective tissue and blood vessels^{8,23}. Inversely, the 7q11.23
158 duplication is associated with aortic dilation due to the presence of an additional copy of *ELN*
159 and other genes in the 7q11.23 region^{22,24,25}. In addition to *ELN*, several other genes in the
160 locus 7q11.23 such as *CLIP2*, *GTF2I*, *GTF2IRD1* and *LIMK1* have also been linked to
161 supraventricular aortic stenosis arising from the 7q11.23 duplication. Chromatin interaction
162 analysis suggested a strong enrichment of regulatory elements in 7q11.23 genomic risk locus
163 which may interact with promotor and/or enhancers of *ELN*. Moreover, we found significant
164 eQTL linking candidate variants within the locus and aortic tissue from GTEx, suggesting the
165 possibility of tissue-specific alterations in gene expression.

166
167 Other genes previously associated with aortic diseases among our discovered genomic risk loci
168 include *TBX20* in the locus 7q14 reported in patients with coarctation of the aorta²⁶; *PRDM6*
169 (5q23) and *MASP1* (4q34) for which mutation in the genes have been reported in children with
170 patent ductus arteriosus^{27,28}. Interestingly, the locus 5q23 (*PRDM6*) along with the locus 17p13
171 (*SMG6 – SRR*) has been previously related to aortic root size⁶. Furthermore, our findings
172 highlight multiple independent loci across ancestries in the critical cardiovascular region 4q31-
173 35 harboring *HAND2* a the transcription factor responsible for reprogramming of fibroblast into
174 cardiomyocytes; deletion of this locus have been associated with multiple type congenital heart
175 defect¹²⁻¹⁴. Moreover, targeted deletion of *HAND2* within the neural crest derived cells in mouse
176 models induce defects in the outflow-tract septation and blood vessel formation²⁹.

177
178 Our findings also highlight loci previously associated with cardiovascular phenotypes including
179 abdominal aortic aneurysm³⁰, carotid intima thickness³¹, two independent coronary artery

180 disease loci³², and multiple previously reported blood pressure risk loci³³ (table S3). These
181 findings suggest a shared genetic architecture between AsAoD and cardiovascular diseases
182 and risk factors.

183
184 Our gene level association studies identified 147 trait associations among which 19 genes were
185 also found to be significantly enriched in multiple tissues and cell types including heart, blood
186 vessels, and cells transformed fibroblast; highlighting a potential role of these genes in functions
187 related to development, maintenance, or regulation of aorta structure and diameter. This finding
188 is concordant with our tissue enrichment analysis that showed significant enrichment of GWAS
189 signals in the aorta, arteries, heart and other predominantly smooth muscle cell tissues.

190
191 AsAoD displayed a high heritability in line with other continuous measurements of human
192 anatomy such as height and head circumference³⁴. However, genetic determinants of the aortic
193 outflow tract size are likely under purifying selection as comparative anatomy suggests the
194 physiological demands of cardiac output are relatively invariant across a wide range of
195 mammalian body sizes³⁵. In contrast to AsAoD, height demonstrates evidence of different
196 selection pressures within different populations³⁶. The genetic architecture underlying measures
197 of high heritability are in concert with our clinical observations for the PRS. The PRS derived
198 from the European GWAS is strongly predictive of disease risk in not only Europeans, but is
199 also reasonably predictive of disease risk in Hispanic and African American populations. As the
200 predictive characteristics of a European-derived PRS in Hispanic and African American
201 populations are likely due in part to the degree of European admixture, the stratified and trans-
202 ethnic meta-analysis offer a unique possibility to improve predictions across populations for a
203 highly heritable trait. While the risk estimates were positive and statistically significant across all
204 replication cohorts, estimates in FinnGen and in the African Americans strata of the MVP

205 appeared smaller which together strongly suggest the need for population-specific studies of
206 AsAoD to derive population-specific risk scores for thoracic aneurysm.

207

208 Clinical decision making regarding medical and surgical treatment of thoracic aortic aneurysm
209 centers around the size of the aneurysm and surrounding vasculature³⁷. Our data suggest that
210 inheritance of common and rare genetic variation are a primary determinant of risk for
211 aneurysmal dilation. Additionally, the findings from mendelian randomization support the
212 efficacy of blood pressure reduction for primary prevention of thoracic aneurysm^{38,39}, and
213 suggest that the reported therapeutic benefits of lipid-lowering therapies on ascending thoracic
214 aortic aneurysms is likely to be confounded^{40,41}.

215

216 Our study has a number of important limitations. While our analyses of disease risk included
217 multiple diverse populations from the United States, the PRS of ascending aortic diameter was
218 constructed from individuals of European descent. In order to broaden the utility of clinical
219 prediction while simultaneously gaining a more complete understanding of the genetic
220 architecture of cardiovascular anatomy, similar studies be performed across human populations
221 worldwide. While we have identified common variation surrounding known developmental
222 regulators of aortic morphogenesis, our findings also displayed strong overlap the with genetic
223 determinants of blood pressure which may represent physiological exposure of the ascending
224 aorta to a distending force. Of note the UK Biobank enrolled individuals between the ages of 40
225 to 60 years; a study of aortic diameter performed in infancy might be less reflective of a lifetime
226 of exposure to blood pressure and other aspects of physiology, lifestyle, and growth.

227 Additionally, we strongly suspect that the healthy cohort bias has removed individuals with
228 extremes of aortic diameter or pathology which influences our genetic findings⁴². Measurements
229 of aortic size were automated while are data are consistent with previous population-based
230 samples, our computational approach may inadvertently introduce error. Altogether our findings

231 identify known developmental and physiological connections to aortic biology and pathology and
232 strongly support our conclusion that *bona fide* genetic effects dominate the signals observed.

233

234 **Conclusion**

235 Collectively, our data suggest ascending aorta diameter derived from automated measurements

236 is highly heritable with numerous genetic determinants distributed across the entire genome.

237 Many signals are clearly linked to developmental, anthropometric, and physiological

238 characteristics, and a polygenic predictor is strongly predictive of clinically silent and highly

239 morbid thoracic aneurysmal disease across populations. Our data convincingly demonstrate a

240 primary causal role of blood pressure management in reducing the dilation of the aorta and

241 minimizing the risk of progression to aneurysmal disease while strongly suggesting the lack of

242 causal protective effect of lipid lowering therapies. Overall our findings translate the genetic

243 determinants of normal variation in the size of the aorta both forward and backward;

244 simultaneously identifying determinants of early cardiovascular development while also

245 providing a new approach to thoracic aortic disease.

246

247 **METHODS**

248 **Design study populations**

249 **UK Biobank Genetic and Imaging Dataset**

250 The UK-Biobank (UKB) is a publicly available research database combining genomic
251 information with clinical and prospectively obtained imaging data^{43,44}. Amongst the 500,000
252 volunteer participants aged 37-73 years recruited between the years of 2006 and 2010, 100,000
253 individuals were selected for participation in the imaging study of Brain, Heart, and Abdominal
254 magnetic resonance imaging (MRI). Due to the design of the imaging protocol, (UK Biobank
255 Limited. Information Leaflet: UK Biobank Imaging Assessment Visit
256 <http://www.ukbiobank.ac.uk/wp-content/uploads/2017/04/Imaging-Information-Leaflet.pdf>)
257 individuals receiving MRI were more healthy than the overall UKB population. The imaging and
258 clinical data are combined with over 90 million Variants, indels and large structural variants was
259 obtained from genotyping and imputation of all 500,000 UKB participants^{45,46}.

260

261 **Ethical statement**

262 Ethical approval for the use of UKB Imaging and clinical data along with consent from
263 participants was obtained by the National Health Service National Research Ethics Service (ref:
264 11/NW/0382) and data use approved under applications 15860, 13721, and 24983. The MVP,
265 and Penn Biobank were used as external validation of the association between the PRS of
266 AsAoD and thoracic aortic disease.

267

268 **The Million veteran program (MVP)**

269 As previously described³³ MVP includes participants over age 18 who served in the United
270 States military and are a longitudinal cohort of active users of the Veteran Health Administration
271 (VA) of any age that have been recruited from more than 60 VA Medical Centers nationwide
272 since 2011 with current enrollment at >825,000. Informed consent was obtained from all

273 participants to provide blood for genomic analysis and to access electronic health record (EHR)
274 data within the VA prior to and after enrollment. At the time of our primary analysis, imputed
275 genetic information was available for up to 459,000 participants assigned to white-European;
276 Black-African and Hispanic ancestries using the HARE algorithm⁴⁷

277

278 **The FinnGen Study**

279 A thoracic aortic aneurysm phenotype was derived from the Finnish national hospital registry
280 and death registry using ICD-9 and ICD-10 codes (listed below) as a part of FinnGen project in
281 176,899 unrelated individuals. Patients and control subjects in FinnGen provided informed
282 consent for biobank research, based on the Finnish Biobank Act. Additional separate research
283 cohorts with study-specific consents collected prior the start of FinnGen (August 2017) were
284 transferred to the Finnish biobanks after approval by Fimea, the National Supervisory Authority
285 for Welfare and Health. Recruitment protocols followed the biobank protocols approved by
286 Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa
287 (HUS) approved the FinnGen study protocol Nr HUS/990/2017. The FinnGen project is
288 approved by Finnish Institute for Health and Welfare (THL), approval number
289 THL/2031/6.02.00/2017, amendments THL/1101/5.05.00/2017, THL/341/6.02.00/2018,
290 THL/2222/6.02.00/2018, THL/283/6.02.00/2019), Digital and population data service agency
291 VRK43431/2017-3, VRK/6909/2018-3, the Social Insurance Institution (KELA) KELA
292 58/522/2017, KELA 131/522/2018, KELA 70/522/2019 and Statistics Finland TK-53-1041-17.

293 The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze
294 5 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67,
295 BB2018_71, BB2019_7 Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank
296 HUS/359/2017, Auria Biobank AB17-5154, Biobank Borealis of Northern Finland_2017_1013,

297 Biobank of Eastern Finland 1186/2018, Finnish Clinical Biobank Tampere MH0004, Central
298 Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001.

299

300 **The Penn Medicine Biobank**

301 The Penn Medicine Biobank is a genomic and precision medicine cohort of individuals receiving
302 care in the University of Pennsylvania Health System. Currently >60,000 participants have
303 actively consented for linkage of biospecimens with electronic health record data for broad
304 health related research. Participants have been genotyped on either the Illumina QuadOmni
305 platform at the Regeneron Genetics Center, or either the Illumina GSA V1 or GSA V2 platforms
306 at the Children's Hospital of Philadelphia Center for Applied Genomics. Standard quality control
307 pipelines were employed and the datasets were combined using an imputation based
308 approach⁴⁸ The data was imputed to 1000G Phase3 v5 reference panel using the Michigan
309 Imputation Server⁴⁹ Genetic ancestry was inferred from principal components derived from
310 common, high-quality variants using SMARTPCA. Related individuals were removed from the
311 dataset based on a kinship coefficient of 0.25 or greater.

312

313 **Measurement of ascending aortic diameter in the UK Biobank imaging cohort**

314 At the time of analysis there, the cardiac MRI imaging in the UK Biobank was available for a
315 subset of 36,201 participants released in two batches: at the first imaging visit (started in 2014)
316 where imaging for ~29,000 participants was released, and a second batch where cardiac MRI
317 was release for an additional ~7,201 participants.

318

319 The calculation of ascending aorta diameter was obtained from the series labeled
320 "*CINE_segmented_Ao_dist*" which is a cinematic view of a full cardiac cycle captured on a

321 transverse plane image of the thorax at approximately T4 at the bifurcation of the main
322 pulmonary artery⁴⁶. To calculate the diameter of the ascending aorta we first performed pre-
323 processing step scaling pixel values to fit in the 0-255 range and cropping the images in the
324 series to become a uniform size of 128x128 pixels. We then selected the first image in each
325 series which represented diastolic blood flow. These procedures provided a uniform image size
326 and pixel range to work with when performing calculations. We next applied a Gaussian filter to
327 the image to smooth edges and reduce noise, followed by a second Gaussian filter and a
328 standard Hough circle transform⁵⁰ specifying the desired identification of two circles, the
329 minimum distance between the two circles, and the minimum and maximum radius of the two
330 circles using the open CV package. We used these identified circles as the markers for the
331 measurements of both ascending (circle 1) and descending aorta (circle 2) by calculating the
332 diameter of the circle and multiplying by the image ratio as identified in the DICOM metadata. A
333 publicly available vignette containing related code can be found online
334 (https://github.com/priestlab/aorta_houghcircle). After quality control, the ascending aorta
335 diameter (AsAoD) was derived for 36,021 participants (29,000 participants from the first release
336 and 7,021 participants from the second release)

337

338 **Genome wide association study**

339 At the time of analysis 35,062 UK Biobank participants from different ancestry background
340 (including white European, African and Afro-Caribbean, East Asian, and South Asian) had both
341 MRI imaging data and genetic data available. We performed a genome wide association study
342 of the MRI derived AsAoD on unrelated individual within each ancestry group (32,2215 White
343 European, 262 African/Afro-Caribbean, 441 South Asian, and 133 East Asian. We followed by a
344 transethnic meta-analysis of 33031 participants from all ancestry group as well as a meta-
345 analysis on non-White European participant (836 participants). Individual ancestry group where
346 defined using a combination of self-reported ethnicity and genetic information through principal

347 component clustering (figure S10). The association between Variants and ascending aorta
348 diameter were performed using using linear regression in PLINK with adjustment on age, sex,
349 body surface area, and 10 principal components. Variants with MAC lower than 5, imputation
350 quality less than 0.6 and that was deviating from hardy Weinberg equilibrium were excluded
351 from the analysis. As a sensitivity analysis, we also performed the association with AsAoD
352 indexed on the body surface area (BSA) and observed similar results. The transethnic meta-
353 analysis was performed using the classical standard error approach with the software METAL⁵¹.
354 We applied Bonferroni correction for multiple testing, variants with $p < 5e-08$ were consider
355 significantly associated with AsAoD.

356

357 **Definition of locus and identification independent set of Variants**

358 Genome wide genomic risk locus, lead and candidate variants were identified using FUMA¹⁶. A
359 genomic risk locus was defined as a 500kb interval in which one or multiple Variants reached
360 genome wide significant threshold. LD blocks within 500kb of each other were merged into one
361 locus. Within each genomic locus, independent variants were defined as those with a correlation
362 less than 0.6 (based on LD structure in 10K white British from the UKB). Finally, candidate
363 variants were defined as those with $R^2 > 0.6$ with an independent variant and a p-value < 0.05 .
364 Our set of new genomic risk loci were identified using different step; we first identified genomic
365 risk loci within each ethnic group. Second, we identify the set of genomic risk loci in the
366 transethnic meta-analysis. Third we searched for overlapping between genomic loci from the
367 transethnic meta-analysis and genomic loci identified in each ethnic group. We then categorized
368 our final set of genomic risk loci into 1) replicated across all ethnic group if candidate variants in
369 the locus had consistent effect direction across all group and the heterogeneity p-value > 0.05 in
370 the transethnic meta-analysis; 2) replicated in at least two studies if directionality of the effect
371 were consistent directionality across at least 2 ethnic groups and at the p-value of heterogeneity
372 between 0.05 and 1×10^{-06} ; and 3) ancestry specific locus if candidate variants in the locus were

373 present in only one ancestry group. Additionally, for a genomic locus that reach genome wide
374 significance at the ancestry specific analysis but was not replicated in the trans-ethnic meta-
375 analysis, we performed a random effect meta-analyses if the directionality of effect was
376 consistent in at least two ethnic groups. Additionally, we performed a step wise procedure
377 implemented in GCTA⁵² to select independently associated Variants followed by a joint
378 conditional analysis to estimate the joint effect the subset of independently associated variant.
379 Standard diagnostics were performed for all association tests (figure S11).

380

381 **Variant functional annotation and chromatin interaction**

382 To further investigate the role of variants with suggestive association, we performed annotation
383 of variants with p-value less than 1e-05 from the discovery cohort using Haploreg version 4¹⁵.
384 The variant annotation included Enhancer and promoter histone marks, variants located in
385 transcription factor binding sites (TFBS) identified from ChIP-Seq experiments (ENCODE
386 Project Consortium, 2011); potential regulatory motif altered; closest annotated gene; and
387 dbSNP functional annotation. Additional annotation of variants with possible clinical relevance
388 were performed using CLINVAR.

389

390 **Heritability estimate and genetic correlations with other complex traits**

391 We used LD score regression to estimate the heritability explained by the genetic variation
392 captured in our population in the entire genome (global SNP-heritability) as well as the
393 proportion of heritability estimate in different area of the genome (local SNP-heritability)⁵³. A
394 genome-wide genetic correlation analysis was performed to investigate a shared genetic basis
395 between Aorta diameter and 242 complex traits and diseases. The pairwise genetic coefficients
396 were estimated between our AsAoD summary statistic, and each of the 242 precomputed and
397 publicly available GWAS summary statistics for complex traits and diseases by using LD score
398 regression through LD Hub v1.9.3 (<http://ldsc.broadinstitute.org>). Additional genetic correlation

399 was computed using LDscore regression for blood pressure phenotype based on the summary
400 statistic of Warren et al⁵⁴ which was not available in the LD Hub v1.9.3 repository. Each pair of
401 genetic correlation were considered significant if the p-value were less 1×10^{-04} based on
402 Bonferroni correction for multiple testing.

403

404 **Gene, pathway, and tissue enrichment**

405 To prioritize genes, pathways and tissues involved in the genetic architecture of Ascending
406 aorta morphology, we conducted a number of downstream analysis which involved several
407 analytical approached but all using the GWAS summary statistics of AsAoD. The Multi-marker
408 Analysis of GenoMic Annotation (MAGMA) v1.09 gene, gene-set, and tissue expression
409 analysis, implemented in FUMA^{16,17} was used to perform gene, gene set, and tissue enrichment
410 analysis. Finally, S-PrediXcan⁵⁵ was used to predict tissue-specific gene expression and
411 association with Aortic tissue with eQTL summary statistics for 52 tissues including 48 tissues
412 from GTEx V8 as reference panel. These analyses incorporated genotype covariance matrices
413 based on a random sample of 10,000 UKB participants to account for LD structure.
414 Colocalization analysis was performed to address the issue of LD-contamination in S-PrediXcan
415 analyses. Input data were identical to those evaluated by S-PrediXcan and colocalization was
416 restricted to only variants included in the gene as designated by S-PrediXcan.

417

418 **Polygenic risk score modeling**

419 We developed a weighted polygenic risk score (PRS) of AsAoD to predict the risk of aortic
420 aneurysms and their risk factors. The PRS was developed based on a summary statistic of a
421 subset of 20,642 UKB White European then tested on the remaining 11,573 unrelated UKB
422 white European with ascending aorta diameter available from the cardiac MRI. The weighted
423 polygenic risk score (PRS) was defined as the sum of the allelic effects (β) of variants
424 contributing to the variation to the ascending aorta diameter across the genome for each

425 individual. The number of variants to include in the polygenic risk scoring was defined using a
426 pruning and thresholding methods implemented in PLINK version 1.90. Briefly, the algorithm (--
427 clump) used a linkage disequilibrium-driven clumping procedure to form “clumps” around
428 variants associated with variation in ascending aorta diameter. We defined a R2 threshold of 0.8
429 for clumping and a p-value threshold of 0.01. To maximize the PRS replication on external
430 sample, insertions-deletions were removed before the clumping procedure. A final set of 92,299
431 variants were included in the PRS calculation. For each variant contributing to the PRS, the
432 assigned weight was to the effect size estimate (β) of the risk allele for the corresponding
433 variant derived from the AsAoD summary statistic of the discovery stage. The genomic risk
434 score for each individual was estimated by summing the number of alleles carried by each
435 individual multiplied by the weight (β) as follows:

$$PRS_{ind} = \sum_{i=1}^n \beta X_i$$

436 Where PRS_{ind} represents a polygenic risk for a given individual, n represents the total number
437 of variants included in the PRS, and β is represent the weight (effect size) for the risk allele X of
438 a variant i . X_i can take the value 0 (no risk allele), 1 (one risk allele), or 2 (two risk alleles)
439 corresponding to the number of risk alleles X carried by an individual for the given variant. To
440 account for potential residual variability of the PRS in the target population, we centered the
441 score sum of PRS to a mean of 0 and a standard deviation of 1 ($\mu=0$, $SD=1$).

442 We tested and validated our PRS in four separate independent samples. First we examined the
443 subset of 11,573 unrelated UKB white Europeans with ascending aorta diameter available from
444 the first and second instance of MRI Imaging release. Although our validation sample was a
445 subset of the UKB participants, this sample was completely independent from the discovery set
446 from which the AsAoD summary statistic was derived. The association between AsAoD and the
447 PRS was performed using linear regression with adjustment on age, sex, BSA, and the top five
448 principal components.

449

450 **Association between PRS for AsAoD and Aortic diseases**

451 The association between Aortic diseases defined by diagnostic codes and the PRS of AsAoD
452 initially was performed on the subset of 316,640 unrelated white British who did not have MRI
453 imaging data available at the time of primary analysis. This was followed by external validation
454 of the PRS in the Million veteran program (MVP); The Penn Biobank; and The FinnGen
455 Biobank.

456

457 **Clinical modeling of thoracic aortic disease**

458 Each replication cohort obtained phenotypic information from administrative or diagnostic coding
459 related to the specific occurrence of thoracic aortic disease. International Classification of
460 Disease 9 and 10 (ICD-9 codes: 441.1, 441.2, 441.01 and ICD-10 codes: I71.01, I71.1, I71.2);
461 Office of Population and Censuses Surveys (OPCS-4 codes: K33.*, L18.2, L19.2, L20.2, L21.2,
462 L22.1, L27.3, L28.3); and Current Procedural Terminology (CPT: 2107426-2107627, 2211645-
463 2211647, 42740410-42740416, 42740439, 45887730-45890065). For survival modeling of
464 thoracic aortic aneurysm in the UKB individuals with congenital anomalies of the outflow tracts
465 (ICD-10 Q25), syndromic disease involving the aorta (ICD-10 Q87*, Q96, Q93.82), or traumatic
466 injury to the heart or aorta (ICD-10 S25.0) were excluded.

467

468 **PheWAS of Polygenic risk score**

469 We evaluated the correlation between the genetic architecture of the ascending aorta diameter
470 and all phenotypes available in the UKB using a phenome-wide association approach
471 (PheWAS) in which the genetic predictor is the AsAoD PRS and the outcome is the UKB
472 phenotype. Phenotypes were obtained from the Global biobank Engine⁵⁶ which include blood
473 biomarkers adjusted on Statin intake; diseases diagnosis obtained from a combined ICD10
474 codes, medication, self-reported medical condition, cancer registry, Brain MRI, physical

475 measurement, medication, family history of diseases, cognitive function, and physical activity.

476 Additionally, diseases diagnosis was obtained using ICD10 derived Phecode⁵⁷.

477 The association between the PRS and each phenotype was performed on 316,640 unrelated
478 white British with without MRI imaging data available at the time of the analysis using linear
479 regression for continuous traits and logistic regression for binary traits with adjustment on age,
480 sex and the top five principal components.

481

482 **Mendelian randomization**

483 To evaluate a causal relation between enlargement of aorta, blood pressure and blood Lipids
484 values, we performed a Mendelian randomization analyses for four lipid phenotypes: LDL, HDL;
485 TG and TC; and three blood pressure phenotypes: SBP, DBP, and PP. The genetic instrument
486 for each phenotype were defined as variants genome-wide significantly ($P < 5 \times 10^{-8}$) associated
487 the exposure and with $R^2 < 0.001$. All clumping was performed using the TwoSampleMR
488 package using Europeans from 1000G as reference panel. Genetic instruments were obtained
489 from the summary statistics of Warren et al⁵⁴ and Willer et al⁵⁸, were used respectively for blood
490 pressure and lipid phenotypes. We used the Inverse-variance weighted MR methods for the
491 primary analysis^{59,60}, with weighted-median MR performed as sensitivity analysis, allowing for
492 up to 50% of the weight of each instrument to be drawn from invalid instruments while
493 controlling type-I error. We performed diagnostics including leave-one-out, single-SNP, funnel-
494 plot, and MR-PRESSO to evaluate for evidence of heterogeneity and horizontal pleiotropy.
495 Additionally, we performed the MR-PRESSO⁶¹ test to identify evidence of horizontal pleiotropy,
496 test for a global horizontal pleiotropy, and identify outliers followed by MR re-estimate after
497 outlier correction, and finally by performing a test for distortion which consist of testing if the
498 causal estimate is significantly different after outlier adjustment.

499

500 **Funding**

501 Funding from the Department of Veterans Affairs Office of Research and Development, Million Veteran
502 Program Grant 1I01BX002641

503

504 NIH R00HL130523 to JRP. Stanford MCHRI Seed Grant to CGT.

505

506 The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH
507 4386/31/2016) and eleven industry partners (AbbVie Inc, AstraZeneca UK Ltd, Biogen MA Inc, Celgene
508 Corporation, Celgene International II Sàrl, Genentech Inc, Merck Sharp & Dohme Corp, Pfizer Inc.,
509 GlaxoSmithKline, Sanofi, Maze Therapeutics Inc., Janssen Biotech Inc). Following biobanks are
510 acknowledged for collecting the FinnGen project samples: Auria Biobank (www.auria.fi/biopankki), THL
511 Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern
512 Finland ([https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-](https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx)
513 [English.aspx](https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx)), Finnish Clinical Biobank Tampere ([www.tays.fi/en-](http://www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere)
514 [US/Research_and_development/Finnish_Clinical_Biobank_Tampere](http://www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere)), Biobank of Eastern Finland
515 (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki),
516 Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) and
517 Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). All Finnish
518 Biobanks are members of BBMRI.fi infrastructure (www.bbmri.fi).

519

520 **Acknowledgements**

521 The authors wish to thank Daniela Zanetti PhD, Matthew Aguirre AB, and Mengyao Yu PhD for technical
522 assistance with aspects of the analysis, and Risto Kajanne for assistance with administrative aspects of
523 the FinnGen resource.

524

525

526 **REFERENCES**

- 527 1. Stojanovska, J., Cascade, P. N., Chong, S., Quint, L. E. & Sundaram, B. Embryology and
528 imaging review of aortic arch anomalies. *Journal of Thoracic Imaging* **27**, 73–84 (2012).
- 529 2. Lopez, L. *et al.* Relationship of Echocardiographic Z Scores Adjusted for Body Surface
530 Area to Age, Sex, Race, and Ethnicity: The Pediatric Heart Network Normal
531 Echocardiogram Database. *Circ. Cardiovasc. Imaging* **10**, (2017).
- 532 3. Lemaire, S. A. & Russell, L. Epidemiology of thoracic aortic dissection. *Nature Reviews*
533 *Cardiology* **8**, 103–113 (2011).
- 534 4. Aday, A. W., Kreykes, S. E. & Fanola, C. L. Vascular Genetics: Presentations, Testing,
535 and Prognostics. *Current Treatment Options in Cardiovascular Medicine* **20**, (2018).
- 536 5. Saeyeldin, A. A. *et al.* Thoracic aortic aneurysm: unlocking the “silent killer” secrets.
537 *General Thoracic and Cardiovascular Surgery* **67**, (2019).
- 538 6. Wild, P. S. *et al.* Large-scale genome-wide analysis identifies genetic variants associated
539 with cardiac structure and function. *J. Clin. Invest.* **127**, 1798–1812 (2017).
- 540 7. McBride, K. L. *et al.* Inheritance analysis of congenital left ventricular outflow tract
541 obstruction malformations: Segregation, multiplex relative risk, and heritability. *Am. J.*
542 *Med. Genet.* **134 A**, 180–186 (2005).
- 543 8. Pinard, A., Jones, G. T. & Milewicz, D. M. Genetics of Thoracic and Abdominal Aortic
544 Diseases: Aneurysms, Dissections, and Ruptures. *Circulation Research* **124**, 588–606
545 (2019).
- 546 9. Renard, M. *et al.* Clinical Validity of Genes for Heritable Thoracic Aortic Aneurysm and
547 Dissection. *J. Am. Coll. Cardiol.* **72**, 605–615 (2018).
- 548 10. Elefteriades, J. A. *et al.* Indications and imaging for aortic surgery: Size and other
549 matters. *J. Thorac. Cardiovasc. Surg.* **149**, S10–S13 (2015).
- 550 11. Paruchuri, V. *et al.* Aortic Size Distribution in the General Population: Explaining the Size

- 551 Paradox in Aortic Dissection. *Cardiology* **131**, 265–272 (2015).
- 552 12. Xia, M., Luo, W., Jin, H. & Yang, Z. HAND2-mediated epithelial maintenance and integrity
553 in cardiac outflow tract morphogenesis. *Dev.* **146**, (2019).
- 554 13. Strehle, E. M. *et al.* Genotype-phenotype analysis of 4q deletion syndrome: Proposal of a
555 critical region. *Am. J. Med. Genet. Part A* **158 A**, 2139–2151 (2012).
- 556 14. Song, K. *et al.* Heart repair by reprogramming non-myocytes with cardiac transcription
557 factors. *Nature* **485**, 599–604 (2012).
- 558 15. Ward, L. D. & Kellis, M. HaploReg: a resource for exploring chromatin states,
559 conservation, and regulatory motif alterations within sets of genetically linked variants.
560 *Nucleic Acids Res.* **40**, D930-4 (2012).
- 561 16. Watanabe, K., Taskesen, E., Van Bochoven, A. & Posthuma, D. Functional mapping and
562 annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1–11 (2017).
- 563 17. Watanabe, K., Umićević Mirkov, M., de Leeuw, C. A., van den Heuvel, M. P. & Posthuma,
564 D. Genetic mapping of cell type specificity for complex traits. *Nat. Commun.* **10**, (2019).
- 565 18. McInnes, G. *et al.* Global Biobank Engine: enabling genotype-phenotype browsing for
566 biobank summary statistics. *bioRxiv* 304188 (2018). doi:10.1101/304188
- 567 19. Davis, A. *et al.* Diameters of the normal thoracic aorta measured by cardiovascular
568 magnetic resonance imaging; correlation with gender, body surface area and body mass
569 index. *J. Cardiovasc. Magn. Reson.* **15**, 1–3 (2013).
- 570 20. Pearce, W. H. *et al.* Aortic diameter as a function of age, gender, and body surface area.
571 *Surgery* **114**, 691–697 (1993).
- 572 21. Curran, M. E. *et al.* The elastin gene is disrupted by a translocation associated with
573 supravalvular aortic stenosis. *Cell* **73**, 159–168 (1993).
- 574 22. Angelov, S. N., Zhu, J., Hu, J. H. & Dichek, D. A. What's the skinny on elastin deficiency
575 and supravalvular aortic stenosis? *Arteriosclerosis, Thrombosis, and Vascular Biology* **37**,
576 740–742 (2017).

- 577 23. Merla, G., Brunetti-Pierri, N., Piccolo, P., Micale, L. & Loviglio, M. N. Supravalvular Aortic
578 Stenosis. *Circ. Cardiovasc. Genet.* **5**, 692–696 (2012).
- 579 24. Earhart, B. A. *et al.* Phenotype of 7q11.23 duplication: A family clinical series. *Am. J.*
580 *Med. Genet. Part A* **173**, 114–119 (2017).
- 581 25. Morris, C. A. *et al.* 7q11.23 Duplication syndrome: Physical characteristics and natural
582 history. *Am. J. Med. Genet. Part A* **167**, 2916–2935 (2015).
- 583 26. Kirk, E. P. *et al.* Mutations in cardiac T-box factor gene TBX20 are associated with diverse
584 cardiac pathologies, including defects of septation and valvulogenesis and
585 cardiomyopathy. *Am. J. Hum. Genet.* **81**, 280–291 (2007).
- 586 27. Atik, T. *et al.* Novel MASP1 mutations are associated with an expanded phenotype in
587 3MC1 syndrome. *Orphanet J. Rare Dis.* **10**, 128 (2015).
- 588 28. Sirmaci, A. *et al.* MASP1 mutations in patients with facial, umbilical, coccygeal, and
589 auditory findings of carnevale, malpuech, OSA, and michels syndromes. *Am. J. Hum.*
590 *Genet.* **87**, 679–686 (2010).
- 591 29. Holler, K. L. *et al.* Targeted deletion of Hand2 in cardiac neural crest-derived cells
592 influences cardiac gene expression and outflow tract development. *Dev. Biol.* **341**, 291–
593 304 (2010).
- 594 30. Bradley, D. T. *et al.* A variant in LDLR is associated with abdominal aortic aneurysm.
595 *Circ. Cardiovasc. Genet.* **6**, 498–504 (2013).
- 596 31. Franceschini, N. *et al.* GWAS and colocalization analyses implicate carotid intima-media
597 thickness and carotid plaque loci in cardiovascular outcomes. *Nat. Commun.* **9**, (2018).
- 598 32. Harst, P. van der & Verweij, N. Identification of 64 Novel Genetic Loci Provides an
599 Expanded View on the Genetic Architecture of Coronary Artery Disease. *Circ. Res.* **122**,
600 433 (2018).
- 601 33. Giri, A. *et al.* Trans-ethnic association study of blood pressure determinants in over
602 750,000 individuals. *Nat. Genet.* **51**, 51–62 (2019).

- 603 34. Yang, X. L. *et al.* Three Novel Loci for Infant Head Circumference Identified by a Joint
604 Association Analysis. *Front. Genet.* **10**, (2019).
- 605 35. Dewey, F. E., Rosenthal, D., Murphy, D. J., Froelicher, V. F. & Ashley, E. A. Does Size
606 Matter?-Clinical Applications of Scaling Cardiac Size and Function for Body Size.
607 *Circulation* **117**, 2279–2287 (2008).
- 608 36. Guo, J. *et al.* Global genetic differentiation of complex traits shaped by natural selection
609 in humans. *Nat. Commun.* **9**, (2018).
- 610 37. Goldfinger, J. Z. *et al.* Thoracic aortic aneurysm and dissection. *Journal of the American*
611 *College of Cardiology* **64**, 1725–1739 (2014).
- 612 38. Milewicz, D. M., Prakash, S. K. & Ramirez, F. Therapeutics Targeting Drivers of Thoracic
613 Aortic Aneurysms and Acute Aortic Dissections: Insights from Predisposing Genes and
614 Mouse Models. *Annu. Rev. Med.* **68**, 51–67 (2017).
- 615 39. Muiño-Mosquera, L. *et al.* Efficacy of losartan as add-on therapy to prevent aortic growth
616 and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind
617 clinical trial. *Acta Cardiol.* **72**, 616–624 (2017).
- 618 40. Taylor, A. P. *et al.* Statin Use and Aneurysm Risk in Patients with Bicuspid Aortic Valve
619 Disease. *Clin. Cardiol.* **39**, 41–47 (2016).
- 620 41. Toganel, R., Benedek, T. & Chitu, M. Response to Statin Use and Aneurysm Risk in
621 Patients with Bicuspid Aortic Valve Disease. *Clinical Cardiology* **39**, 307–308 (2016).
- 622 42. Aguirre, M., Rivas, M. A. & Priest, J. Phenome-wide Burden of Copy-Number Variation in
623 the UK Biobank. *Am. J. Hum. Genet.* **105**, 373–383 (2019).
- 624 43. Collins, R. What makes UK Biobank special? *Lancet* **379**, 1173–1174 (2012).
- 625 44. Sudlow, C. *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a
626 Wide Range of Complex Diseases of Middle and Old Age. *PLOS Med.* **12**, e1001779
627 (2015).
- 628 45. Bycroft, C. *et al.* Genome-wide genetic data on ~500,000 UK Biobank participants.

- 629 *bioRxiv* 166298 (2017). doi:10.1101/166298
- 630 46. Petersen, S. E. *et al.* UK Biobank's cardiovascular magnetic resonance protocol. *J.*
631 *Cardiovasc. Magn. Reson.* **18**, (2016).
- 632 47. Fang, H. *et al.* Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in
633 Genome-wide Association Studies. *Am. J. Hum. Genet.* **105**, 763–772 (2019).
- 634 48. Verma, S. S. *et al.* Imputation and quality control steps for combining multiple genome-
635 wide datasets. *Front. Genet.* **5**, 1–15 (2014).
- 636 49. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat. Genet.* **48**,
637 1284–1287 (2016).
- 638 50. Biasioli, L. *et al.* Automated localization and quality control of the aorta in cine CMR can
639 significantly accelerate processing of the UK Biobank population data. *PLoS One* **14**,
640 (2019).
- 641 51. METAL: fast and efficient meta-analysis of genomewide association scans. Available at:
642 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922887/>. (Accessed: 19th May 2020)
- 643 52. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: A tool for genome-wide
644 complex trait analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).
- 645 53. Shi, H., Kichaev, G. & Pasaniuc, B. Contrasting the Genetic Architecture of 30 Complex
646 Traits from Summary Association Data. *Am. J. Hum. Genet.* **99**, 139–153 (2016).
- 647 54. Warren, H. R. *et al.* Genome-wide association analysis identifies novel blood pressure
648 loci and offers biological insights into cardiovascular risk. *Nat. Genet.* **49**, 403–415
649 (2017).
- 650 55. Barbeira, A. N. *et al.* Exploring the phenotypic consequences of tissue specific gene
651 expression variation inferred from GWAS summary statistics. *Nat. Commun.* **9**, 1–20
652 (2018).
- 653 56. McInnes, G. *et al.* Global Biobank Engine: enabling genotype-phenotype browsing for
654 biobank summary statistics. *bioRxiv* (2018).

- 655 57. Wu, P. *et al.* Developing and Evaluating Mappings of ICD-10 and ICD-10-CM codes to
656 Phecodes. *bioRxiv* 462077 (2018). doi:10.1101/462077
- 657 58. Willer, C. J. *et al.* Discovery and refinement of loci associated with lipid levels. *Nat.*
658 *Genet.* **45**, 1274–1285 (2013).
- 659 59. Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization analysis with
660 multiple genetic variants using summarized data. *Genet. Epidemiol.* **37**, 658–665 (2013).
- 661 60. Burgess, S., Scott, R. A., Timpson, N. J., Smith, G. D. & Thompson, S. G. Using
662 published data in Mendelian randomization: A blueprint for efficient identification of causal
663 risk factors. *Eur. J. Epidemiol.* **30**, 543–552 (2015).
- 664 61. Verbanck, M., Chen, C. Y., Neale, B. & Do, R. Detection of widespread horizontal
665 pleiotropy in causal relationships inferred from Mendelian randomization between
666 complex traits and diseases. *Nat. Genet.* **50**, 693–698 (2018).
- 667